Travere Therapeutics, Inc. — Director's Dealing 2021

May 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Travere Therapeutics, Inc. (TVTX)
CIK: 0001438533
Period of Report: 2021-05-11

Reporting Person: Rosenberg Noah L. (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-11	Common Stock	S	375	$19.14	Disposed	45969	Direct
2021-05-12	Common Stock	S	375	$19.46	Disposed	45594	Direct

Footnotes

F1: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.